Fuller & Thaler Asset Management
KIN

Fuller & Thaler Asset Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Fuller & Thaler Asset Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-152,660
Closed -$1.27M – 499
2019
Q2 		$1.27M Sell
152,660
-700
-0.5% -$6.04K 0.01% 325
2019
Q1 		$1.41M Sell
153,360
-2,820
-2% -$28.6K 0.02% 313
2018
Q4 		$1.71M Buy
+156,180
New +$1.97M 0.02% 290

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Fuller & Thaler Asset Management's KIN Position: Q3 2019 in Review

Fuller & Thaler Asset Management sold out of Kindred Biosciences, Inc. (KIN) in Q3 2019, closing a stake of 152,660 shares — an estimated $1.27M sold.

Fuller & Thaler Asset Management first reported a position in KIN in Q4 2018 and held it in 3 quarters. The position peaked at $1.71M in Q4 2018. 72 funds tracked by Wall St. Rank hold KIN as of Q3 2019.

  • Fuller & Thaler Asset Management reported no remaining Kindred Biosciences, Inc. position as of Q3 2019 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 152,660 Kindred Biosciences, Inc. shares in Q3 2019, an estimated $1.27M.
  • Fuller & Thaler Asset Management first reported a position in Kindred Biosciences, Inc. in Q4 2018 and held it in 3 quarters.
  • Fuller & Thaler Asset Management's Kindred Biosciences, Inc. position peaked at $1.71M in Q4 2018.
  • 72 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2019.

Based on Fuller & Thaler Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.